Abigail Matthews
Physician Assistant · Cartersville, GANPI 1497082499
Payments from drug & device makers
Across 542 payments — averaging $18.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Lilly USA, LLC$1K
- Biohaven Pharmaceuticals, Inc.$991
- AbbVie$821
- Pfizer$675
- AstraZeneca$614
- plus $5K from 40 others
What the payments were for
- Consulting fees$8008%
- Travel & lodging$671%
- Food & beverage$9,22091%
- Education$260%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$800
- BREZTRI$105
- AIRSUPRA$105
- FARXIGA$105
How this compares
$10,113 in reported general payments places this provider in the 95th percentile of 3,581 physician assistant providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 140 | $168,222 |
| JardianceEmpagliflozin | 84 | $115,889 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 62 | $60,615 |
| OzempicSemaglutide | 44 | $56,953 |
| FarxigaDapagliflozin Propanediol | 46 | $49,426 |
| EliquisApixaban | 33 | $37,223 |
| JanuviaSitagliptin Phosphate | 32 | $34,657 |
| XareltoRivaroxaban | 20 | $31,454 |
| RybelsusSemaglutide | 15 | $27,278 |
| ProliaDenosumab | 13 | $22,658 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 13 | $21,625 |
| TrulicityDulaglutide | 15 | $16,774 |
| MyrbetriqMirabegron | 13 | $15,447 |
| BelsomraSuvorexant | 20 | $9,589 |
| Tresiba Flextouch U-200Insulin Degludec | 16 | $9,423 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $1,036 | $184,996155 claims |
| Boehringer IngelheimJardiance | $151 | $115,88984 claims |
| Novo NordiskOzempic, Rybelsus | $1,134 | $84,23059 claims |
| GSKTrelegy Ellipta | $409 | $60,61562 claims |
| AstraZenecaFarxiga | $614 | $49,42646 claims |
| MerckJanuvia, Belsomra | $187 | $44,24652 claims |
| PfizerEliquis | $675 | $37,22333 claims |
| Johnson & JohnsonXarelto | $60 | $31,45420 claims |
| AmgenProlia | $528 | $22,65813 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $208 | $21,62513 claims |
| Astellas Pharma US IncMyrbetriq | $193 | $15,44713 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $83 | $2,776297 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,581 physician assistant providers in Georgia.
Other physician assistant in Cartersville
- Douglas DiruggieroCartersville$1.3M
- Jennifer CobbsAtlanta$1M
- A BrunnerStockbridge$1M
- Joseph LangshawCalhoun$887K
- Alison MoeAtlanta$410K
- Maggie SchreckAtlanta$389K
- Lisa HillMarietta$190K
- Laura BishopBrunswick$103K
- Jaime AckermanAtlanta$84K
- Richard BurrellBrunswick$69K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.